These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27503183)

  • 1. Febuxostat in Hyperuricemic Patients With Advanced CKD.
    Lim DH; Oh JS; Ahn SM; Hong S; Kim YG; Lee CK; Choi SW; Yoo B
    Am J Kidney Dis; 2016 Nov; 68(5):819-821. PubMed ID: 27503183
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
    Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
    Lee JW; Lee KH
    Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: A PRISMA-compliant article.
    Zeng XX; Tang Y; Hu K; Zhou X; Wang J; Zhu L; Liu J; Xu J
    Medicine (Baltimore); 2018 Mar; 97(13):e0161. PubMed ID: 29595642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion.
    Terawaki H; Hoshi H; Kazama JJ
    Clin Exp Nephrol; 2017 Apr; 21(2):356-357. PubMed ID: 28247173
    [No Abstract]   [Full Text] [Related]  

  • 6. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
    Sezai A; Unosawa S; Taoka M; Osaka S; Sekino H; Tanaka M
    Ann Thorac Cardiovasc Surg; 2020 Aug; 26(4):202-208. PubMed ID: 31748427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
    Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M
    J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
    Sircar D; Chatterjee S; Waikhom R; Golay V; Raychaudhury A; Chatterjee S; Pandey R
    Am J Kidney Dis; 2015 Dec; 66(6):945-50. PubMed ID: 26233732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD.
    Sarvepalli PS; Fatima M; Quadri AK; Taher AR; Habeeb A; Amreen F; Parveen BN; Rajaram KG
    Saudi J Kidney Dis Transpl; 2018; 29(5):1050-1056. PubMed ID: 30381500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
    Levy G; Shi JM; Cheetham TC; Rashid N
    Perm J; 2018; 22():17-142. PubMed ID: 30201087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urate-lowering efficacy and renal safety of febuxostat in patients with hyperuricemia and stage 4-5 chronic kidney disease not yet on dialysis: A meta-analysis of observational studies.
    Jeong HJ; Park WY; Kim SH; Dalbeth N; Son CN
    Semin Arthritis Rheum; 2022 Oct; 56():152073. PubMed ID: 35914389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricemia.
    Nishizawa T; Taniura T; Nomura S
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):887-92. PubMed ID: 26164850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is It Time to Start Treating Asymptomatic Hyperuricemia?
    Levy G; Cheetham TC
    Am J Kidney Dis; 2015 Dec; 66(6):933-5. PubMed ID: 26593311
    [No Abstract]   [Full Text] [Related]  

  • 14. A formula predicting the effective dose of febuxostat in chronic kidney disease patients with asymptomatic hyperuricemia based on a retrospective study and a validation cohort
.
    Aoun M; Salloum R; Dfouni A; Sleilaty G; Chelala D
    Clin Nephrol; 2020 Aug; 94(2):61-69. PubMed ID: 32589132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: A randomized controlled study.
    Tsuruta Y; Kikuchi K; Tsuruta Y; Sasaki Y; Moriyama T; Itabashi M; Takei T; Uchida K; Akiba T; Tsuchiya K; Nitta K
    Hemodial Int; 2015 Oct; 19(4):514-20. PubMed ID: 25998500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Febuxostat for the chronic management of hyperuricemia in patients with gout.
    Chinchilla SP; Urionaguena I; Perez-Ruiz F
    Expert Rev Clin Pharmacol; 2016; 9(5):665-73. PubMed ID: 26942273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
    Tanaka K; Nakayama M; Kanno M; Kimura H; Watanabe K; Tani Y; Hayashi Y; Asahi K; Terawaki H; Watanabe T
    Clin Exp Nephrol; 2015 Dec; 19(6):1044-53. PubMed ID: 25676011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of febuxostat on serum urate level in Japanese hyperuricemia patients.
    Yamamoto T; Hidaka Y; Inaba M; Ishimura E; Ooyama H; Kakuda H; Moriwaki Y; Higami K; Ohtawara A; Hosoya T; Nishikawa H; Taniguchi A; Ueda T; Yamauchi T; Fujimori S; Mineo I; Yamanaka H
    Mod Rheumatol; 2015 Sep; 25(5):779-83. PubMed ID: 25671406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.
    Mallat SG; Al Kattar S; Tanios BY; Jurjus A
    Curr Hypertens Rep; 2016 Oct; 18(10):74. PubMed ID: 27696189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics and Therapeutic Efficacy of Febuxostat in Patients with Severe Renal Impairment.
    Hira D; Chisaki Y; Noda S; Araki H; Uzu T; Maegawa H; Yano Y; Morita SY; Terada T
    Pharmacology; 2015; 96(1-2):90-8. PubMed ID: 26183164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.